Cellens Announces Collaboration with Bruker BioAFM to Advance Mechanobiology Technology for Cancer Detection
BOSTON–(BUSINESS WIRE)–Cellens, Inc., an early-stage cancer diagnostic company pioneering in applying mechanobiology and machine learning analysis today announced that it is collaborating with Bruker BioAFM, a business unit of Bruker(Nasdaq: BRKR), to develop the world’s first clinical diagnostic tests that leverage multi-parametric, single-cell biophysical markers and machine learning. Based on cellular biophysical markers attained using Bruker’s advanced atomic […]
